) recently announced that it has finished enrolling patients for
the initial stage of the two-stage NORTH phase II trial. The
trial is being conducted to assess IMGN901, for the first-line
treatment of extensive disease small-cell lung cancer (SCLC).
With patient enrollment being completed, the company should be
able to report results from a planned interim analysis on
progression free survival (PFS) at six months in the second half
of 2013. The NORTH trial is to include 120 patients in all.
IMGN901 is being evaluated with etoposide and carboplatin
(E/C), the standard of care for this cancer variant, in the NORTH
trial. Once interim results are available, the company intends to
use the findings to decide on the development path for
We note that other companies are also developing candidates
for SCLC treatment. In Jan 2013, Cerulean Pharma Inc. announced
that the first patient was dosed in a phase II study being
conducted with its SCLC candidate, CRLX101. The purpose of the
study is to compare the efficacy of the candidate to topotecan, a
) is also developing its candidate amrubicin for SCLC.
We remind investors that ImmunoGen had initiated the North
trial in Mar 2012. ImmunoGen also conducted a phase I study on
IMGN901 for multiple myeloma. The candidate was evaluated with
lenalidomide plus dexamethasone, a standard of care for this
disease. We note that IMGN901 has orphan drug label for both SCLC
and multiple myeloma in the US and EU.
ImmunoGen presently carries a Zacks Rank #3 (Hold).
Comparatively, other biotech stocks look better positioned. These
). They both carry a Zacks Rank #1 (Strong Buy).
AGENUS INC (AGEN): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis
IMMUNOGEN INC (IMGN): Free Stock Analysis
(NVZMY): ETF Research Reports
To read this article on Zacks.com click here.